Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.66 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | HTR6 | P50406 | 4/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6344225 | 0.99 | HDAC1 (0.65) | HDAC6HDAC1CA1CA2HTR6 | |
| SCHEMBL6335989 | 0.86 | HDAC1 (0.67) | HDAC6HDAC1CA1CA2HTR6 | |
| SCHEMBL6422248 | 0.86 | HDAC1 (0.69) | HDAC6HDAC1CA1CA2HTR6 | |
| Hydrochloric Acid SCHEMBL9615118 | 0.85 | HDAC1 (0.67) | HDAC6HDAC1CA1CA2HTR6 | |
| SCHEMBL6342434 | 0.84 | HDAC1 (0.70) | HDAC6HDAC1CA1CA2HTR6 | |
| Trifluoroacetic Acid SCHEMBL6423027 | 0.84 | HDAC6 (0.67) | HDAC6HDAC1CA1CA2HTR6 | |
| Hydrochloric Acid SCHEMBL6339587 | 0.83 | HDAC1 (0.69) | HDAC6HDAC1CA1CA2HTR6 | |
| SCHEMBL6341009 | 0.80 | HDAC6 (0.71) | HDAC6HDAC1CA1CA2HTR6 | |
| SCHEMBL12951842 | 0.80 | HDAC6 (1.00) | HDAC6HDAC1HDAC10 | |
| SCHEMBL6651209 | 0.78 | MCHR1 (0.45) | HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6964970-B2 | Antibacterial compounds | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-11-15 | — | — | US | disclosed |
| EP-1180030-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2004-11-24 | — | — | EP | disclosed |
| US-20030232850-A1 | Antibacterial compounds | DEBIOPHARM INTERNATIONAL SA (CH) | 2003-12-18 | — | — | US | disclosed |
| US-6573272-B1 | Antibacterial compounds | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2003-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232850-A1 | Antibacterial compounds | RER1, FAR1, REL | HDAC6 317/4885HDAC1 61/4885CA1 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.